Oslo, Norway, 31 August 2021: Reference is made to the stock exchange release by
Photocure ASA ("Photocure" or the "Company") published on 30 August 2021
regarding exercise of share options.
The price for option shares sold by the primary insider, Geoffrey Coy, VP &
General Manager US Operations, has been determined at a price of NOK 113.6148
per share.
The primary insider having exercised options has used the net proceeds from the
sale of option shares to purchase 7,126 shares in Photocure at a price per share
of NOK 113.6148 as follows:
The shares are purchased at the stated price from Photocure's holding of own
shares. Following the transaction Photocure will hold 21,010 own shares.
Primary insider notification pursuant to the market abuse regulation article 19
is attached.
For further information, please contact:
Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com
All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.
This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.